Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients
Sponsor: Novartis Pharmaceuticals
Summary
The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.
Official title: Asciminib Effectiveness in Real World Setting of Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL); a Retrospective Review Study of Patients From the Asciminib Managed Access Program (ASCERTAIN)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
37
Start Date
2024-12-16
Completion Date
2025-09-17
Last Updated
2026-06-12
Healthy Volunteers
No
Conditions
Locations (18)
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Sydney, New South Wales, Australia
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Hong Kong, China
Novartis Investigative Site
Le Chesnay, France
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Ascoli Piceno, Italy
Novartis Investigative Site
Bari, Italy
Novartis Investigative Site
Catania, Italy
Novartis Investigative Site
Cuneo, Italy
Novartis Investigative Site
Pescara, Italy
Novartis Investigative Site
Torino, Italy
Novartis Investigative Site
Rotterdam, Netherlands
Novartis Investigative Site
Islamabad, Pakistan
Novartis Investigative Site
Rawalpindi, Pakistan
Novartis Investigative Site
Bialystok, Poland
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
London, United Kingdom